| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CBLIF |
| Uniprot No | P27352 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-417aa |
| 氨基酸序列 | STQTQSSCSVPSAQEPLVNGIQVLMENSVTSSAYPNPSILIAMNLAGAYNLKAQKLLTYQLMSSDNNDLTIGQLGLTIMALTSSCRDPGDKVSILQRQMENWAPSSPNAEASAFYGPSLAILALCQKNSEATLPIAVRFAKTLLANSSPFNVDTGAMATLALTCMYNKIPVGSEEGYRSLFGQVLKDIVEKISMKIKDNGIIGDIYSTGLAMQALSVTPEPSKKEWNCKKTTDMILNEIKQGKFHNPMSIAQILPSLKGKTYLDVPQVTCSPDHEVQPTLPSNPGPGPTSASNITVIYTINNQLRGVELLFNETINVSVKSGSVLLVVLEEAQRKNPMFKFETTMTSWGLVVSSINNIAENVNHKTYWQFLSGVTPLNEGVADYIPFNHEHITANFTQY |
| 预测分子量 | 45.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CBLIF重组蛋白的虚构参考文献示例(基于领域常见研究方向，实际文献需通过学术数据库核实)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant CBLIF Protein in Plant Defense Signaling*
**作者**：Zhang L, et al.
**摘要**：本研究通过大肠杆菌表达系统成功制备了CBLIF重组蛋白，并验证其在植物免疫反应中的功能。实验表明，CBLIF通过与MAPK信号通路相互作用，调控病原相关分子模式(PAMP)触发的防御反应。
2. **文献名称**：*Purification and Characterization of CBLIF Recombinant Protein for Cancer Therapeutic Applications*
**作者**：Kim S, Park JH
**摘要**：作者利用哺乳动物细胞表达体系纯化CBLIF重组蛋白，分析其抑制肿瘤细胞增殖的机制。结果表明，CBLIF通过调控EGFR信号通路降解，在体外和体内模型中显著抑制肺癌生长。
3. **文献名称**：*Structural Insights into CBLIF Recombinant Protein via Cryo-EM*
**作者**：Wang Y, et al.
**摘要**：通过冷冻电镜技术解析CBLIF重组蛋白的三维结构，揭示其与E3泛素连接酶复合物的结合模式，为开发靶向蛋白降解药物提供结构基础。
4. **文献名称**：*Optimization of CBLIF Recombinant Production in Yeast Expression Systems*
**作者**：Gomez-Reyes F, et al.
**摘要**：研究比较了毕赤酵母和酿酒酵母系统中CBLIF重组蛋白的表达效率，优化了发酵条件，获得高纯度蛋白用于后续酶活性和稳定性测试。
---
**注意**：以上文献为示例性质，实际研究中请通过PubMed、Web of Science等平台检索真实文献。若需具体文献，建议提供更完整的蛋白全称或研究背景。
CBLIF (Cbl-interacting protein) recombinant protein is a genetically engineered protein derived from the CBLIF gene, which encodes a key regulatory molecule involved in cellular signaling pathways. Originally identified as an interacting partner of the Casitas B-lineage lymphoma (Cbl) family of ubiquitin ligases, CBLIF plays a critical role in modulating receptor tyrosine kinase (RTK) signaling, endocytosis, and downstream processes such as cell proliferation, differentiation, and apoptosis. The Cbl proteins are known to function as negative regulators of RTKs by targeting them for ubiquitination and subsequent degradation. CBLIF, through its interaction with Cbl, fine-tunes these regulatory mechanisms, influencing cellular responses to growth factors and cytokines.
The recombinant form of CBLIF is typically produced using expression systems such as *E. coli*, yeast, or mammalian cell cultures, enabling large-scale production with high purity and consistency. This recombinant approach allows precise control over post-translational modifications, enhancing its utility in biochemical and functional studies. Researchers employ CBLIF recombinant protein to investigate its structural domains, binding partners, and mechanistic roles in signaling cascades. It is particularly valuable in studying diseases linked to dysregulated RTK signaling, including cancers, immune disorders, and neurodegenerative conditions. Additionally, it serves as a tool for drug discovery, aiding in the development of inhibitors or modulators targeting Cbl-CBLIF interactions. Its application extends to diagnostic assays and therapeutic protein engineering, underscoring its versatility in both basic research and translational medicine. The availability of recombinant CBLIF has significantly advanced our understanding of cellular regulation and potential therapeutic interventions.
×
